



ersonal use only

Investor Briefing

Gold Coast Investment Showcase

Merrill Gray – MD & CEO

11 JUNE 2026





Disclaimer

IMPORTANT INFORMATION

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX: ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Past performance is not indicative of future performance.

FORWARD-LOOKING STATEMENTS

The presentation may contain certain "forward-looking statements". Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", "aim", "estimate", "target", "anticipate", "believe", "continue", "objectives", "outlook", "guidance" or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.


NOT AN OFFER OF SECURITIES

This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.


AnteoBind™ NXT, Anteo X®, Anteo S™ and Ultranode® are trademarks of AnteoTech. The use of registered and pending trademark symbols throughout the presentation is implied. All \$ quoted are AUD unless otherwise stated.

An Advanced Chemical and Materials Company

Performance enhancing chemicals used in Next Generation Lithium-ion Batteries (LIB) and Diagnostics



Life Sciences




- Diagnostic immunoassays market: US\$ 56 B p.a. revenue , 9% CAGR (2024)^{1,2}

Advanced Battery Technologies



- High silicon anode market: US \$540 M growing at 45% CAGR (2025)
- Ceramic coated separators: US\$2 B growing at 21% CAGR (2024)³

Further Potential Applications



- Superconductors
- Water treatment (PFAS removal)
- Coatings
- Filtration
- Man-made Textiles

Specialising in surface modification

Delivering molecular-level “cross-linking” (molecule-to-molecule and molecule to surface) solutions to customers globally

Protected through 17 patents

1 = Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company

2= Precedence Research, Coherent Market Research

3 =<https://www.researchandmarkets.com/reports/6089608/ceramic-coated-separators-market-global>

AnteoTech's Products and Technology

Two commercial businesses in markets with ~US\$60 billion p.a. in sales annually
Record level requests for samples

Life Sciences



- AnteoBind NXT™
- New Products for launch in FY2027
 - CLIA (Chemiluminescence)
Fast, sensitive infectious disease testing and wellbeing monitoring
 - ELISA (Enzyme-Linked Immunosorbent Assay)
Detecting and quantifying antibodies, antigens, proteins and bodily fluids

Advanced Battery Technologies



- Anteo X®
Cross linking performance additive
- SiMRAX
Binder strengthening system
- Ultranode™
High Silicon Anode formulation/design
- Anteo S™
Separator structural performance additive



Capital Structure and Corporate Overview

INTRODUCTION

Market Capitalisation

\$88m
as at 9 June 2026

Capital Structure (as at 9 June 2026)

Cash in Bank	\$12.8 million (Pro-forma 31 March 2026 ⁴ +\$9.5 m option exercise 29 May, net of fees)
Shares	3,259.8 million
Unlisted Options	292 million (30% expire in 2026, 52% in 2028). Employee/Director options 26%
Top 20 Holders	Hold 23% of shares

Directors



Glenda McLoughlin
Non-Executive Chair
Investment Banker with Morgan Stanley, Credit Suisse and Barclays. Commercial Advisor and ASX Founder. Energy and Infrastructure sector expertise.




Dr. Geoff Cumming
Non-Executive Director
Career spanning research to sales and marketing and Executive roles with Roche Also on INOVIQ Ltd (IIQ) Board. Biotechnology and Healthcare sector expertise.



Merrill Gray
Managing Director/CEO
Appointed 19 August 2025 (NED, 30 Jan., Interim MD 18 April 2025). ASX Founder and MD/CEO. Energy incl. Battery (CAM (LFP/LMFP), Graphite and Recycling) plus Hydrogen and Renewables experience.

Share Price – 6 months



Recent Commercial Milestones

1. Independent, third-party validation of Ultranode™ 95 MLP for Drones
2. Xerabrid high performance Separator collaboration in South Korea
3. Cosmo Bio appointed as Japanese Life Sciences distributor
4. CLIA collaboration with large life sciences company

⁴= Source: Refer ASX Release dated 20 April 2026 “Quarterly Activities/Appendix 4C Cash Flow Report”

AnteoTech (ASX:ADO) Investment Proposition


- ✓ \$12.8 million cash, with Revenues and no debt (Pro-forma 31 March 2026⁴)
- ✓ Two commercial businesses addressing markets exceeding US\$60 B⁴
- ✓ Record samples requests and evaluations and growing qualified sales pipeline
- ✓ Independent, third-party validation of Ultranode™ 95 performance in commercial cell format. US defence drone market entry strategy underway.
- ✓ Ultranode™ 70 wearables validation⁴ underway.
- ✓ New products opening large addressable markets: Anteo S™ and SiMRAX
- ✓ Expansion into new diagnostic immunoassay markets: Chemiluminescence (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA)⁴
- ✓ Multiple commercial and partnership catalysts over the next 12 months

⁴= Source: Refer ASX Release dated 20 April 2026 “Quarterly Activities/Appendix 4C Cash Flow Report”



Progress Against FY2026 Strategy


At 11 June 2026:
 19 ABT samples &
 14 LS samples
 under evaluation





Anatomy of a Lithium-ion Battery (LIB)

Electrochemical unit schematic



Ultranode™ brings silicon's potential into LIB

Silicon stores around 10 x more Li⁺ by weight and 3 x more Li⁺ by volume than graphite



versus



⁶C - Graphite

371 mAh/g

¹⁴Si - Silicon

3,579 mAh/g

Active material type	Specific active material capacity
Elemental micro Silicon (Si)	3,579 mAh/g *
Si/C (silane)	1,850 mAh/g ^
SiOx-Li	1,500 mAh/g
Graphite	371 mAh/g*

* Theoretical maximum

^ Subject to supplier

Leading in High Silicon Anode Technology



ULTRANODE™

Application	Automotive & eVTOLs	3C Markets and Micro-mobility	UAS, Drones and Defence
Ultranode technology	Ultranode® X	Ultranode® 70	Ultranode® 95
Cycle life	High (>1,000 @ 80%)	Medium (>500 @ 80%)	Medium (>200 @ 80%)
Coating capacities	Medium (700-1,100 mAh/g)	Medium (700-1,100 mAh/g)	High (1,800-2,400 mAh/g)
Supply Chain Options	Korea, China, US	Korea, China, US	Korea, China, US
Commercially scaled-up	✓	✓	✓
Engagement pathway	<ol style="list-style-type: none"> 1. Technology partnership 2. Joint Development Agreements 3. Licensing 	<ol style="list-style-type: none"> 1. Ultranode samples 2. Ultranode + Cathode sample packs 	Ultranode samples and Ultranode + Cathode sample packs

Ultranode™ 95 – Superior Energy and Flight Time.

High capacity and cost-effective anode technology



Ultranode 95's unique Value Proposition



Superior Wh/kg at anode/cell level

>2,400mAh/g of anode coating capacity possible
At cell level, Specific Energy (Wh/kg) of >390 possible



Lowest \$/kWh silicon active material

Highly cost-effective anodes



Supply chain security

Existing silicon raw material supply from US, KR, EU



Highly customisable



Leading in Cross-linking Performance Additive



ANTEO STM

ANTEO X[®]

SIMRAX

Cross-linker for Ceramic Coated Separators (CCS)

Cross-linker for Silicon Anodes

Anteo X + SWCNT Combination Product for Silicon Anodes

Safer and Thinner Separators

- Safe batteries by reducing potential thermal runaway and fires.

Improved Performance

- Improved cycle life by more than 35%¹
- Reduced anode expansion by up to 40%²

Improved Cost Efficiency


- Reduction in CNT content by 50%¹
- Reduction in binder content by more than 2wt%³

All-in-one solution for high Si anodes

- Performance additive combining high quality carbon nanotube products with unique crosslinking agents

New market opportunities with Anteo S™

- Anteo S™ is used in ceramic coatings on separators to:
 - Improve thermal stability
 - Reduce thermal runaway and fires
 - Improve puncture resistance
- Anteo S™ potential lies in high volume sales for ESS and EVs



Source: Grand View Research (2024) - Battery Separator Market Size, Share & Trends Analysis Report by Material, by Application, by region, and Segment Forecasts, 2024–2032 and IDTechEX (2024) - Li-ion Battery Separator Technologies and Markets 2024–2034



Escondido, California (September 2024): A BESS fire at a substation resulted in significant damage. The incident involved overheating of battery cells.
 Source: <https://eticaag.com/thermal-runaway-in-battery-energy-storage-systems-bess/>

Strategic Collaboration and Sales Agreement

26 May 2026 with



Indian, Japanese, South Korean and US Life Sciences Market development

- Chemiluminescence (CLIA) White Paper published March 2026 showing AnteoBind NXT™ activation to outperform market incumbents:
 - Up to 1.8 x higher signal-to-blank (improved sensitivity)
 - Up to 6 x lower antibody usage (reduced cost)
 - Activation reduced from 20 hours to 2 hours (workflow improvements)
- Local Indian business development resources engaged in mid April 2026
- Cosmo Bio engaged as Japanese Distributor in May 2026
- South Korea, Japan and India under assessment as potential CLIA product pilot markets
- US market push –In Late July 2026 AnteoTech will attend the Association for Diagnostics & Laboratory Medicine (ADLM) conference – New product launch/showcasing will take place
- Strategic Partnership development is continuing




CLIA Market Entry Opportunity

- Global CLIA market estimated as US\$13 billion p.a. in sales in 2024⁵
- Consumables 66% of the market⁶
- Antibodies plus CLIA particles 50% to 90% of total Consumables
- AnteoTech is positioned to move up the value chain⁷

Rethink Bioconjugation To Cut Costs and Improve Assay Performance

Whitepaper Published: April 10, 2026



Source: <https://www.technologynetworks.com/tn/white-papers/rethink-bioconjugation-to-cut-costs-and-improve-assay-performance-411567?spl=6c1c5089d3134d1099408b8096a779c9>


5= Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends.

6= Source: Grand View Research, Chemiluminescence Immunoassay Market (2024–2030); <https://www.grandviewresearch.com/industry-analysis/chemiluminescence-immunoassay-market>

7= Source: AnteoTech Ltd technical “White Paper” entitled: Enhancing CLIA Performance: A Comparative study. AnteoBind™ NXT vs Tosyl-activated magnetic particle. www.anteotech.com

CLIA Market Entry Strategy

- AnteoTech is assessing the supply of CLIA activation kits to immunoassay manufacturers
- Delivering customers with simplified, high performance, lower cost activation solutions
- Each kit is expected to contain:
 - Magnetic particles sourced through AnteoTech’s global supply network
 - AnteoBind NXT™ activation reagents
 - Optimised protocols for activation and technical support
- Kits are intended to be packaged within target markets to meet local regulatory and customer requirements
- This approach will enable AnteoTech to move further up the value chain





Commercial Execution

SUMMARY

ersonal use only

- ✓ Solid sales pipeline built and being progressed
- ✓ US military drone market focus
 - BIC validation of Ultranode™ 95's performance for drones in commercial cell format achieved
 - 2 x JDAs with US battery manufacturers for drones in progress
- ✓ Wyon validation of Ultranode™ 70 for wearables underway - commercial format test results pending
- ✓ SiMRAX joint product initial customer testing underway and growing interest being received
- ✓ Anteo S™ major separator manufacturer interest
- ✓ CLIA product and market entry options under development



Short Term Targets – Progress made, Growing Momentum

Life Sciences

- New customers in India
- CLIA market entry – Secure strategic partnerships and/or Pilot market entry
- ELISA market entry progression
- Japanese, South Korean and US market expansion



Advanced Battery Technologies

- Drone anode JDAs secured in the US
- Develop Australian defence ecosystem opportunities
- Sales and strategic collaboration for Anteo S™
- Participate in trial battery “Kit” opportunity



Corporate

- Product/Sales Distributor network expansion
- R&D tax rebate claim expedited
- Strategic Partnerships





Come and see us
at our Booth!

Contact:

Merrill Gray

investors@anteotech.com

+61 (07) 3219 0085

www.anteotech.com

ersonal use only





Continued delivery on FY2026 Strategy (Reviewed and refined)



Existing markets where opportunities will continue to be pursued




New opportunities being targeted and pursued

	Strategy	Life Sciences	Advanced Battery Technologies
 India	<ul style="list-style-type: none"> Targeted sales growth through existing network expanding commercialisation pipeline. Securing of strategic partnerships, profit repatriation model basis. 	<ul style="list-style-type: none"> Further expand Serum Institute of India relationship and secure additional similar customers. Work with Austrade and Trade and Investment Queensland (TIQ) 	<ul style="list-style-type: none"> Target E-Mobility and Wearables manufacturers Joint Venture and Joint Product Development (JDA).
 USA	<ul style="list-style-type: none"> Expansion of our customer base Attract strategic partner 	<ul style="list-style-type: none"> Target the Point-of-Care Diagnostics, CLIA and ELISA markets. 	<ul style="list-style-type: none"> Target defence and security via drones and Unmanned Aerial Systems (UAS). Carbon Nanotube JDA.
 South Korea & Japan	<ul style="list-style-type: none"> Expand our customer base/sales Attract strategic partners 	<ul style="list-style-type: none"> Distributors supporting growth Austrade and TIQ support 	<ul style="list-style-type: none"> Distributors supporting growth Austrade and TIQ support
 Europe	<ul style="list-style-type: none"> Expand existing customer base Attract new partners 	<ul style="list-style-type: none"> Global Life Sciences company engagement lateral flow, CLIA and ELISA. 	<ul style="list-style-type: none"> WYON evaluation and validation and new customers

Source: Refer ASX Release dated 10 June 2025 "Strategic Review Outcomes"


The Global Drone Battery Market

A large market with several very different use or end application cases



Rapidly Growing Drone Battery Market

Potential USA Market Opportunity >US\$1.4 Billion



- **Global market size 2024:** US\$8.1billion^A
- **Projected market size by 2034:** US\$42 billion (CAGR: >18%)^A
- **US market by 2034:** ~1/3 of total market^A
- **10% of US market share by 2034^A:** Estimated at \$1.4 billion
- **Geopolitics are impacting growth globally**
- **Policy driven investment and market dynamics examples**
 - US SkyFoundry Act of 2025 and NDDA^B
 - Readiness 2030: European Defence Initiative (~€800B)^{C,D}

^A 2026 Feb: Drone Battery Market Size and Forecast 2026 to 2035
^B 2025 Jul: Sky Foundry Act of 2025
^C 2025 Oct: Europe unveils plans for 'drone wall' to shield continent from Russian threats
^D 2025 Dec: Defence: how the EU is boosting its security

The market share is shown for market-sizing purposes, not as Company revenue projections